This paper is only available as a PDF. To read, Please Download here.
Inhaled cannabis has been shown to reduce chronic pain, however its intoxicating effects
present a clinical limitation. Several studies support the popular notion that CBD
(cannabidiol) can reduce THC (trans-Δ⁹-tetrahydrocannabinol) subjective effects, yet
multiple other studies demonstrate that CBD can actually enhance THC's intoxicating
effects. These discrepancies are dependent upon the two cannabinoids’ ratios and concentrations.
We hypothesize that the majority of medical cannabis products with THC and CBD will
have ratios capable of producing significant acute intoxication, similar to recreational
products. This study subsequently aims to characterize cannabis products available
from dispensaries within ratio and concentration categories, and evaluate whether
the probable effects of products labeled as recreational differ from those labeled
as medical to determine their potential utility for chronic pain. We collected THC
and CBD content from cannabis products offered by 653 dispensaries online from nine
states (CA, CO, ME, MA, NH, NM, RI, VT, WA). A total of 8,505 herbal cannabis products
were recorded, with 6,293 offering information on CBD content. The 72.8% of products
containing CBD (>0%) fall into four clinically meaningful categories: CBD can enhance
THC effects (THC:CBD ratios ≥ 1:1), CBD has no significant effect on THC effects (ratios
∼1:2), CBD can either have no effect or is protective against THC effects (ratios
1: >2<6), or CBD is protective against THC effects (ratios ≤ 1:6). In line with our
hypothesis, the majority of both medical and recreational products with CBD fall into
the foremost listed category (e.g., 66.7% medical, and 67.7% recreational in CO),
with CBD likely potentiating THC effects; and products likely to provide CBD mitigation
of THC effects make up the smallest category (e.g., 6.7% medical, and 9.2% recreational
in CO). Patients seeking medical cannabis with CBD content for chronic pain are therefore
at substantial risk of amplifying THC acute effects. Department of Anesthesiology
- Wake Forest School of Medicine Funds.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.